Clinical Trials
56 trialsA Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
AMPLIFY-201
Elicio Therapeutics
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
GONGCHU Biotechnology Co., Ltd
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
MasterKey-01
Black Diamond Therapeutics, Inc.
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Compugen Ltd
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Ohio State University Comprehensive Cancer Center
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
University of Maryland, Baltimore
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
AbbVie
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
AbbVie
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Altor BioScience
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Alliance for Clinical Trials in Oncology
Spectroscopy With Surface Coils and Decoupling
Memorial Sloan Kettering Cancer Center
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
City of Hope Medical Center
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Duke University
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
CritiTech, Inc.
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Altor BioScience
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Memorial Sloan Kettering Cancer Center
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
Eisai Inc.
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Biological Therapy in Treating Patients With Metastatic Cancer
Duke University
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Cancer Research UK
Gene Therapy in Treating Patients With Cancer
Roger Williams Medical Center